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Compliance to Different Exercise-Training Protocols in Individuals with Chronic 
Obstructive Pulmonary Disease 
 
Rima Wardini 
Rationale: Current guidelines for pulmonary rehabilitation suggest high-intensity 
exercise training for patients with chronic obstructive pulmonary disease (COPD). 
However, compliance to this type of training is problematic. Alternative approaches, such 
as training at the ventilatory threshold and interval training, have been proposed as 
easier to comply with. The objectives of this study were to: 1) compare patient 
compliance to three exercise-training protocols: continuous training at high-intensity 
(CTHI), continuous training at the ventilatory threshold (CTVT), and interval training (IT); 
2) determine if a relationship exists between exercise compliance and baseline self-
efficacy in COPD patients. Methods: Subjects were randomly assigned to one of the 
protocols and trained on a cycle ergometer three times per week for 12 weeks. 
Compliance to the training protocol was measured by attendance and compliance rates 
to the prescribed intensity. Compliance data were obtained through data tracking 
technology allowing second-by-second recording of exercise-training sessions. Self-
efficacy was measured using the Self-Efficacy Scale. Results: Thirty-six subjects with 
moderate to severe COPD participated in the study. Attendance rates did not differ 
significantly between groups (Mean  SD: 70  33% for CTHI, 82  17% for CTVT, 63  
35% for IT, p = 0.229). Mean compliance rates were 85.6 ± 15.0 % for CTHI, 84.1 ± 15.1 
% for CTVT, and 52.0 ± 41.8 % for IT (p=0.07). Self-efficacy did not correlate with mean 
attendance or mean compliance to the prescribed intensity. Conclusion: The present 
study suggests that IT may be associated with lower compliance rates than CTHI and 
CTVT. 
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1. Theoretical Context 
1.1 An Overview of Chronic Obstructive Pulmonary Disease 
 Individuals with respiratory disease have impaired lung function leading to 
breathlessness and inactivity which results in disability, a loss of independence, and 
poor quality of life (Figure 1.1) [1-5]. COPD is comprised of chronic bronchitis and 
emphysema, and is characterized by chronic airflow limitation, hyperinflation, 
inflammation, and systemic manifestations such as skeletal muscle wasting and 
cachexia [2, 4, 6, 7]. It is a chronic illness that is progressive in nature and minimally 
reversible [6].  
 
Figure 1.1 COPD downward spiral. Adapted from la Clinique du Souffle la Solane, Osséja, France 
[8].  
 
Chronic bronchitis is described by the inflammation and swelling of the cells 
lining the bronchi and bronchioles of the lungs leading to narrowing of the airways. The 
inflammation stimulates the production of mucus (sputum), which can cause further 
obstruction of the airways increasing the likelihood of bacterial infections [2, 7]. Clinically, 
symptoms such as cough and sputum production for at least 3 months in each of 2 
consecutive years, serve as a diagnostic criteria for the presence of chronic bronchitis 
[6].   
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Emphysema, on the other hand, is a condition of the lungs where the walls of the 
alveoli, the gas exchanging surfaces of the lungs, are destroyed and loose elasticity 
hindering the outflow of air during exhalation [2, 6]. Dyspnea represents one of the main 
symptoms in patients with emphysema [6]. All COPD patients have airflow limitation 
combining chronic bronchitis and emphysema with the contribution of each varying from 
one patient to another [6].  
 
1.2 Epidemiology 
1.2.1 Prevalence  
COPD is the fourth leading cause of mortality in the world and in Canada and 
represents a major cause of respiratory morbidity [6, 9, 10]. In 2004, COPD was 
responsible for 9,607 deaths in Canada and it is expected to become the third leading 
cause of death in the next 20 years [3, 9]. Unlike other major illnesses with either stable 
or declining mortality rates, COPD is the only disease where mortality continues to rise 
[11]. More than 750, 000 Canadians are diagnosed with COPD, but the actual 
prevalence is thought to be higher since only 6-8% of the population have recorded 
objective criteria fulfilling the diagnosis of this chronic respiratory illness [3, 6, 9, 11]. Up 
to 60-85% of COPD patients remain undiagnosed, since this illness is often detected at 
a clinically apparent and advanced stage [1-3, 9, 12]. The prevalence of the disease is 
expected to increase in the coming years due to continued exposure to COPD risk 
factors and to aging of the population [1, 6, 9, 10].  
 
1.2.2 Social and Economic Burden  
The social and economic burden of COPD is significant [6] and represents a high 
weight to the Canadian healthcare system [12]. Despite declining smoking rates in 
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Canada, the number of COPD hospitalizations is still increasing [11]. Not only is COPD 
the leading cause of hospital admission, it also has a higher readmission rate compared 
to other chronic diseases such as angina, heart failure, diabetes, or hypertension [11]. In 
a cohort of 73 106 Canadian patients who have been hospitalized for the first time for 
severe COPD exacerbation, it was shown that 2 to 3 month [13] following that event 
represented a period of very-high risk of recurrence. Of the 73 106 COPD patients, 
25 290 and 37 935 died at 3.6 and 7.7 years respectively [13].  Other studies have 
shown that 18% of patients suffering from COPD are readmitted to a hospital once and 
14% twice in the same year [12, 14]. In 2008, Mittman et al. reported that the average 
length of hospital stay for COPD exacerbations was 10 days costing $10 000 per stay 
[12, 15]. In the same year, it was reported that COPD incurred approximately $1.5 billion 
in total health care costs in Canada yearly [15]. In addition, COPD mortality rate, within 
one year of exacerbation hospital admission, is shown to be comparable to myocardial 
infarction [12, 16]. In their 2012 report, the Conference Board of Canada suggested that 
an increase of a 140% of direct and indirect costs of COPD would occur by 2030. COPD 
costs are expected to increase from approximately $4 billion in 2010 to approximately 
$9.5 billion by 2030 [17].  
 
1.3 Risk Factors 
1.3.1 Cigarette Smoking 
Cigarette smoking is the principal risk factor contributing to COPD [4, 6]. Indeed, 
it is believed to be responsible for 80 to 90% of COPD cases [4, 6], and virtually all 
COPD patients report a smoking history. The risk related to cigarette smoking is dose-
dependent, where smoking total dose influences lung function and mortality [2, 6, 18, 
19]. Smoking dose can be quantified by total pack years smoked, which is the number of 
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smoking years multiplied by the number of packs smoked per day [6]. Tobacco smoke 
induces a specific inflammation process leading to mucus hypersecretion, alveoli 
destruction, and impairment of the lung defence mechanisms, such as the deterioration 
of the lung’s mucociliary clearance. This in turn creates a susceptibility to infection and 
COPD exacerbations which can lead to further deterioration of lung function [19]. 
However, smoking exposure does not systematically lead to the development of COPD 
[2]. In fact, it has been shown that about 10 to 15 percent of smokers develop this 
respiratory illness [2]. Other underlying factors have been identified which can likely 
explain COPD development in non-smokers [6, 20].  
 
1.3.2 Genes 
 Risk factors for COPD are also believed to be a result of gene-environment 
interaction [6]. A severe deficiency in alpha-1 antitrypsin, a key inhibitor of serine 
proteases, is the most important genetic risk factor for COPD [6, 21]. This genetic deficit 
leads to a precipitated decline in lung function in both smokers and non-smokers [6]. 
Other mediators, such as transforming growth factor beta 1, microsomal epoxide 
hydrolase 1, and tumor necrosis factor alpha, have been implicated in COPD genesis 
[6]. However, their influence on the development of COPD has not yet been fully 
identified.  Alpha-1 antitrypsin deficiency is most commonly seen in individuals originated 
from Northern Europe and is often found in multiple members of the same family who 
develop COPD [6, 22].  
 
1.3.3 Occupational Dust and Chemicals  
Although the effect of occupational dust and chemicals (i.e. organic and inorganic 
dust and fumes) are small compared to those of cigarette smoking, it has been shown 
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that they can contribute to decreased lung function and COPD [2, 6]. An occupational 
health study focusing on certain specific industries, such as plastics manufacturing, 
textile mill products, armed forces, construction and trucking demonstrated that high 
occupational exposure contributed significantly to the cause of COPD [23]. This was 
estimated at 19.2% among smoker and 31.1 % among non-smokers [23]. This is 
consistent with Balmes et al. [24], who studied the contribution of occupational risk 
factors on the burden of COPD, and found that occupational exposures account for 10-
20% of COPD cases.   
 
1.3.4 Indoor and Outdoor Air Pollution 
Indoor pollution is an important risk factor for COPD. In developing countries, 
particularly among non-smoking women, exposure to smoke from biomass fuels and 
heating in poorly ventilated dwellings has been related to increased prevalence of fixed 
airways disease COPD [2, 6].  Indoor air pollution [25] caused by burning of wood and 
other biomass fuels is responsible for the death of 2 million women and children every 
year [6]. The role of outdoor air pollution in COPD is unclear, but high levels of urban air 
pollution may contribute to accelerated decline in lung function, can exacerbate 
symptoms and is known to be harmful for individuals with cardio-respiratory diseases [2, 
6]. 
 
1.3.5 Other Risk Factors  
Asthma: 
 It has been shown that asthmatic adults have a twelve-fold higher risk of 
developing fixed airways disease similar to what is characteristic of COPD [25]. Although 
asthma is characterized by spontaneous reversibility of airway limitation, it has been 
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reported that functional changes of the small airways and alveoli can occur and can lead 
to accelerated lung function decline and increased exacerbations [26]. These patterns of 
airway inflammation and structural remodeling can lead to fixed airflow obstruction in 
some cases of asthma. Studies have shown that the prevalence of fixed airflow 
obstruction among asthmatic patients vary between 20 and 49% [27, 28].    
Lung Development: 
Maternal smoking is associated with increased respiratory infections and low 
birth weight in children, which are both believed to be risk factors for the development of 
COPD in adulthood [2]. Reduced maximally attained lung function is related to COPD 
and therefore any factor affecting lung growth during gestation and childhood increases 
COPD prevalence [2, 6].   
Respiratory Infections: 
Viral and bacterial respiratory infections are often the precursors to acute 
exacerbation of COPD and they are believed to contribute to the progression of the 
disease [6]. Exacerbations are shown to have a significant impact on lung function and 
quality of life deterioration, as well as increased health care utilization.   
Severe childhood infections, which can be explained in some cases by an 
underlying airway hyper-responsiveness, are shown to decrease lung function and 
increase respiratory symptoms later in life [6].  
Age, Sex and Socioeconomic Status: 
Lung function is known to decline with increasing age and may impact on the 
prevalence of COPD as the population ages [2]. In previous studies, a higher proportion 
of men were shown to be affected by COPD [6], however, increasing smoking 
frequencies in women has created sex equality. Today at least 50% of those diagnosed 
with COPD are women [6].  Furthermore, it has been shown that women are more 
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susceptible to cigarette smoke and tend to have a faster decline in FEV1 than male 
smokers [2, 29]. This sex difference could be explained by hormonal factors and by the 
fact that women are more likely to have smaller lungs and larger airways than men, 
which could favour women’s increased sensitivity to cigarette smoke [29].   
Socioeconomic status has been inversely related to COPD development [2, 6].  
However, it is unclear whether this correlation is influenced by other factors such as 
education, nutrition, air pollutants, smoking prevalence, or other social issues [6].       
 
1.4 Pathology, Pathogenesis and Pathophysiology 
1.4.1 Pathology 
COPD is characterized by an abnormal inflammatory response in the lungs 
(Figure 1.2), which represents an innate and adaptive response to long term exposure to 
noxious substances and gases, such as cigarette smoke [6, 30]. COPD comprises 
pathological changes leading to mucous hypersecretion as seen in chronic bronchitis, 
and tissue destruction (emphysema), and disturbance of normal defense mechanisms 
resulting in small airway inflammation and alveolar destruction [30]. These pathological 
changes lead to the main characteristics found in COPD, which includes increased 
resistance to airflow in the small airways, increased lung compliance, air trapping, and 
progressive airflow obstruction [6, 30]. With COPD, the inflammatory and structural 
changes occur in four distinct areas of the lungs; the proximal (central) airway which 
includes the trachea and bronchi, the peripheral airways, the lung parenchyma (which 
include the bronchioles and alveoli), and the pulmonary vasculature which refers to the 
major vessels [6, 7]. In general, these pathological changes increase with disease 





1.4.2.1 Inflammatory Cells and Mediators:  
Noxious stimuli, such as cigarette smoke triggers the activation of inflammatory 
cells such as lymphocytes (T CD4+, T CD8+), macrophages, and neutrophils [6, 31] 
(Figure 1.2).  These inflammatory cells can then potentially release a variety of cytokines 
(interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha) and inflammatory 
mediators such as lipid mediators (leukotriene B4), chemokines (interleukin-8), and 
growth factors (transforming growth factor-beta) interacting with structural cells in the 
airways and lung parenchyma [6, 31, 32].  
 In the proximal airways of COPD patients, an increase in macrophages, 
lymphocytes and neutrophils occur. In addition, an enlargement of the submucosal 
bronchial gland and goblet cell cause hypersecretion of mucus. Other structural changes 
include: airway epithelial squamous metaplasia, ciliary dysfunction, and hypertrophy of 
smooth muscle and connective tissue [6, 30]. In the peripheral airways, the increased 
number of inflammatory cells, lymphoid follicles and fibroblasts cause premature 
bronchiolitis, proliferation of globlet cells and squamous metaplasia as well as 
peribronchial fibrosis and narrowing of the airways [6, 30]. In the lung parenchyma, the 
increasing number of macrophages and lymphocytes lead to alveolar wall destruction 
and loss of epithelial and endothelial cells airway remodelling and parenchymal 
destruction characteristic of COPD [6, 30]. There is also a loss of epithelial and 
endothelial cells leading to alveolar wall destruction. With the development of 
emphysema there is an abnormal enlargement of airspaces distal to terminal 
bronchioles and dilatation and destruction of bronchioles that occurs in the lung 
parenchyma [6, 30]. The possible structural changes that occur in the pulmonary 
vasculature include hypertrophy of smooth muscle, endothelial cell destruction 
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accompanied by thickening of the intima, which can lead to pulmonary hypertension [6, 
30]. 
 
Figure 1.2 Inflammatory mechanisms in COPD [31]. 
 
1.4.2.2 Oxidative stress and Protease-Antiprotease Imbalance:  
 In addition to the presence of inflammation, there is an imbalance between 
proteases and anti-proteases producing or creating oxidative stress in COPD [6, 30, 31]. 
Oxidants are generated by cigarette smoke and by reactive oxygen and nitrogen species 
released from inflammatory cells causing an oxidative burden [6, 30].  Oxidative stress 
biomarkers, such as hydrogen peroxide, are increased in the sputum and systemic 
circulation and this stress is heightened or increased during respiratory exacerbations. 
Oxidative stress can lead to the following adverse outcomes; inactivation of anti-
proteases, stimulation of mucus secretion, activation of inflammatory enzymes (i.e. 
nuclear factor-B) and hence gene expression of pro-inflammatory mediators [6, 30].  
In addition, an imbalance between proteases (responsible for the connective 
tissue break down) and anti-proteases (protecting against connective tissue break-down) 
is seen in COPD. Noxious stimuli lead to oxidative stress which in turn primes several 
inflammatory cells to release proteases (e.g. Proteinase 3, Cathepsins E, and Matrix 
metaproteinases-8) and inhibit the activation of anti-proteases (e.g. Alpha-1 antitrypsin, 
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Elafin and Cystatins) [6, 30]. This imbalance leads to the destruction of the elastin, which 
is a component of the connective tissue of the lung parenchyma, causing emphysema 
[6].     
 
1.4.3 Pathophysiology 
The above mentioned pathologic changes result in physiologic abnormalities, 
such as mucous hypersecretion, ciliary dysfunction, airflow obstruction and 
hyperinflation, and impaired gas exchange. With ongoing disease progression patients 
may further experience right-sided heart failure, and manifest systemic effects such as 
metabolic syndrome (hypertension, hperglycemia and obesity) and pulmonary 
hypertension. 
 
1.4.3.1 Airflow limitation and hyperinflation: 
 In order to understand the process of airflow limitation and hyperinflation, it is 
important to present the four basic lung volumes and the four basic lung capacities 
(Figure 1.3). Lung volumes and lung capacities refer to the volume of air associated with 
different phases of the breathing cycle, where lung volumes are directly measured and 
lung capacities are inferred from lung volumes [33]. Tidal volume (VT) is the amount of 
air that can be inhaled and exhaled in a regular breathing cycle when at rest. Inspiratory 
reserve volume (IRV) is the maximum amount of air that can be forcibly inhaled from the 
end of a tidal inspiration [33]. On the other hand, expiratory reserve volume (ERV) 
represents the maximal amount of air that can be expired at the end of a tidal expiration. 
Residual volume (RV) is defined as the amount of air remaining in the lungs after ERV 
[33].     
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 Lung capacities are subdivisions of total volume that include two or more of the 
four basic lung volumes. Vital capacity (VC) represents maximal volume of air that can 
be forcefully exhaled from the lungs following a maximal inspiration (VC = IRV+TV+ERV) 
[33]. Inspiratory capacity (IC) is defined as the maximal volume of air that can be 
inspired from end expiration (IC = TV+IRV). The volume of air remaining in the lung at 
the end of a normal expiration is known as functional residual capacity (FRC) (FRC = 
RV+ERV) and total lung capacity (TLC) is the volume of air contained in the lungs at the 
end of a maximal inspiration (TLC = RV+IRV+TV+ERV) [33].  
 The two main flow rates that are important to measure in COPD are forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC) [6]. The values 
of these measures in liters and in percent normal predicted, which are determined by 
spirometry, are central in the evaluation and classification of COPD severity. In addition, 
FEV1 to FVC ratio is crucial in the diagnosis of COPD [6].       
Air flow limitation occurs mainly in the small airways and is caused by airway 
remodeling, loss of elastic recoil and destruction of the alveolar matrix [30]. The degree 
of inflammation, fibrosis and luminal secretions in the small airways is correlated with 
reduced FEV1 and FEV1/FVC ratio [6]. With progressive airway obstruction, air is 
trapped during expiration leading to lung hyperinflation (increase in the retrosternal air 
space) [6, 30]. Hyperinflation decreases inspiratory capacity (IC), which in turn causes 
an increase in functional residual volume [6].  These features are believed to be the 
main mechanisms leading to exertional dyspnea and limited exercise capacity which 





Figure 1.3 Basic lung volumes and capacities. TLC: total lung capacity; IC: inspiratory capacity; FRC: 
functional residual capacity; RV: residual volume; IRV: inspiratory reserve volume; VT: tidal volume; ERV: 
expiratory reserve volume; RV: residual volume; VC: vital capacity [33]. 
 
1.4.3.2 Impaired gas exchange:  
  Impaired gas exchange usually occurs in more advanced stages of COPD and is 
mainly characterized by an uneven distribution of both alveolar ventilation and 
pulmonary blood flow, known as ventilation-perfusion ratio (VA/Q) [6, 30, 34].  The 
destruction of alveoli in COPD reduces entry of oxygen (O2) into the systemic circulation, 
and limits carbon dioxide (CO2) uptake in the alveoli to be expired upon exhalation 
causing CO2 trapping in the lungs. This imbalance results in arterial hypoxemia (a 
decreased partial pressure of O2 in the blood) with or without hypercapnia (increased 
levels of CO2 in the blood) in stable disease and during exacerbation [30, 34].   
 
1.4.3.3 Respiratory and peripheral muscle dysfunction: 
In COPD patients, selective wasting of fat-free mass (FFM) coupled with 
impaired respiratory and peripheral muscle function are common [35]. Wasting generally 
occurs in COPD as well as other chronic inflammatory diseases and is an important 
systemic manifestation [35, 36]. The prevalence of tissue depletion (i.e wasting) in 
COPD patients varies between 20 to 35% and is associated with poor survival [35, 37]. 
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It has also been shown that COPD patients have a higher resting energy 
expenditure, which is believed to lead to an imbalance of energy intake and expenditure, 
and thus muscle mass wasting [36]. Possibly as a result of inadequate caloric intake to 
support the increased metabolic requirements of impaired respiration as well as the 
burden imposed by frequent infections, there is a breakdown of cell proteins, in particular 
in the lower muscle extremities, in order to recruit the required amino acids needed for 
protein synthesis and energy metabolism [35].  
 
1.4.4 Sequela  
1.4.4.1 Exercise Intolerance:  
Systemic inflammation and skeletal muscle wasting contribute to limiting the 
exercise capacity in COPD patients [31]. It is of evidence that COPD patients have 
functional impairment that is attributable to the compromise of respiratory function and to 
the presence of systemic components [38, 39]. The main pulmonary factors contributing 
to increased dyspnea and causing exercise limitation is lung hyperinflation. It has been 
shown that the determination of the exercise level of dyspnea is a better predictor of 
mortality than the degree of airflow obstruction (FEV1) [38]. Moreover, the levels of 
arterial oxygen (O2) and carbon dioxide (CO2) have an important influence on COPD 
patients’ exercise capacity. Low levels of arterial O2 and high levels of CO2 compromise 
cardiac function by increasing cardiac load and hyperinflation, which results in increased 
intra-thoracic pressures and decreased exercise capacity [38]. 
Skeletal muscle dysfunction has become an important determinant of exercise 
capacity and a strong predictor of mortality, especially among moderate-to-severe 
COPD patients [39]. Skeletal muscle dysfunction is characterized by the loss of muscle 
strength and endurance associated with alteration of muscle fibre-type (I, IIa, IIx) and 
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leading to decreased oxidative muscle capacity [39].  Moreover, high proportions of 
COPD patients are inactive and tend to have an inadequate nutrition leading to a 
significant loss of muscle mass. Physical inactivity has also been shown to induce 
systemic inflammation mediated by the reduction in the activity of the transcription factor 
peroxisome proliferator-activated-c coactivator (PGC)-1a, which regulates skeletal 
muscle morphology and metabolism [38, 39]. These abnormalities, which are associated 
with loss of muscle strength, are significant determinants of exercise capacity 
independent of COPD severity [38]. In severe COPD, muscle wasting (protein 
degradation) has a profound impact on morbidity, hospitalizations, frequency of 
exacerbations, and mortality [39].     
 
1.4.4.2 Exacerbations: 
Exacerbations can be caused by bacterial and viral infections, air pollution, 
ambient temperature changes and other triggers. It has been hypothesized that during 
acute exacerbations, a disturbance occurs in the equilibrium between protein breakdown 
and synthesis [35]. Neutrophilic inflammation and increased number of eosinophils often 
characterise exacerbations [30].  In mild exacerbations, airflow obstruction is minimally 
affected. However, in severe exacerbations there is an increased imbalance between 
ventilation and perfusion due to; airway inflammation, edema, mucous hypersecretion 
and bronchoconstriction, which lead to pulmonary gas exchange deterioration [30]. 
Reduced ventilation contributes to hypoxic vasoconstriction of pulmonary arterioles 
impairing perfusion and subsequently respiratory muscle fatigue [30]. Pulmonary 
vasoconstriction can result in right ventricle strain, which leads to peripheral edema. 
Respiratory muscle fatigue contributing to hypoxemia, hypercapnia and respiratory 




The systemic inflammation caused by cigarette smoke may contribute to the 
development of comorbidities such as cardiovascular diseases, metabolic disorders and 
some cancers [40].  It has been shown that COPD increases the risk for other diseases 
because of its extrapulmonary effects leading to weight loss, skeletal muscle dysfunction 
and malnutrition [6]. Thus, patients with COPD are at higher risk of developing the 
following; hypertension, diabetes, heart failure, ischaemic heart disease, cancer, 
osteoporosis, depression and anemia [6, 40]. However, it is difficult to determine 
whether these comorbidities were coexistent or whether they are a causal association 
with COPD [40]. COPD patients are believed to often die from other reasons than 
respiratory failure and it is therefore important to evaluate COPD comorbidities when 
considering adequate and successful management of the disease [6, 40].   
 
1.4.4.4 Anxiety and Depression: 
COPD does not only affect pulmonary function of patients, but it also has an 
impact on their cognitive functions, which often translate into anxiety and depression 
disorders [41, 42]. These disorders are markedly enhanced in COPD patients compared 
to the general population, where the prevalence of anxiety and depression are 33% and 
50% respectively [41]. The pathogenesis of these disorders is unclear and the onset can 
occur at any time in the life of COPD patients [41, 42]. Symptoms related to anxiety and 
depression are shown to worsen dyspnea, reduce tolerance and compliance to exercise, 
increase emotional instability, which in turn all lead to increased exacerbations and 
hospitalizations [41]. A lack of comprehension related to the illness, difficulties adjusting 
and accepting the illness with its limitations, solitude, and fear of missing air can all lead 
to anxiety and depression. Therefore, patients affected by COPD should have 
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psychological support, education and medication if necessary to manage the cognitive 
sequela caused by this disease [41, 42].  
 
1.5- COPD Assessment and Evaluation 
1.5.1 Screening, Diagnosis  
Patients with a smoking history presenting with respiratory complaints such as 
dyspnea, chronic cough or sputum production, and exposure to other COPD risk factors 
should be screened and evaluated for the presence of obstructive lung disease [6]. 
 Spirometry is recognized as the gold standard for diagnosis and monitoring of 
COPD [6]. It is necessary to undertake spirometry not only to screen COPD, but also to 
exclude any other possible diagnosis with similar symptoms [6]. Spirometry should 
measure FVC, FEV1, which permits the calculation of the ratio of these measures 
(FEV1/FVC) [6].   Since the ratio FEV1/FVC declines with age and in order to avoid over-
diagnosis of COPD in the older population, it is important to evaluate spirometry results 
by comparing them to appropriate reference values based on age, sex, height, and race 
[6].  However, in order for a true diagnosis to be made, this screening should be 
performed post-bronchodilator [6]. In fact, the presence of COPD is defined by a post-
bronchodilator FEV1/FVC less than 0.70 [6]. COPD patients have decreased FEV1 and 
FVC values and the severity of the disease is generally reflected by the degree of flow 







Table 1.1 Spirometry classifications of COPD 
Stage FEV1/FVC Post-Bronchodilator FEV1 
Stage I: Mild < 0.70 ≥ 80% predicted 
Stage II: Moderate < 0.70 50% to 79% predicted  
Stage III: Severe < 0.70 30% to 49% predicted 
Stage IV: Very severe < 0.70 <30% or <50% plus respiratory failure  
Severity based on post-bronchodilator FEV1. FEV1: forced expiratory volume in one second; FVC: forced 
vital capacity. Adapted from GOLD [6]. 
  
Pulmonary function tests (PFTs), such as the measurements of flow volume 
loops, diffusing capacity (DLCO), inspiratory capacity, lung volumes, are not considered 
routine evaluations [6]. However, these tests are valuable tools to resolve diagnostic 
uncertainties or to determine patient’s condition prior to surgery to assess the risk of 
complications [6]. More importantly, PFTs reveal the presence of hyperinflation in 
support of COPD diagnosis.   
 In addition, the presence of various findings such as hyperinflation, lung 
hyperlucency and rapid narrowing of the vasculature on chest X-ray (CXR) are important 
in COPD diagnosis and in detecting the presence of other important comorbidities such 
as heart failure [6].  Computed tomography (CT) scanning is often used to detect the 
distribution of bullous emphysema in the lung volume reduction surgery is anticipated 
[6].   
Of great importance is the lack of screening for the disease in patients with a 
smoking history even when respiratory symptoms are present, which sometimes leads to 
the prescription of medication without proper disease evaluation and staging. This lack 
of diagnosis also leads to absence of proper treatment strategies until later stages of the 
illness. Part of this occurs due to a lack of easily available access to pulmonary function 
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testing and respiratory specialists. Another problem regarding COPD diagnosis is the 
misclassification of spirometry results, which are often related to poor coaching, 
inaccurate spirometer, or inappropriate interpretation of PFTs by primary physicians [43]. 
Prescription of inhaled medications may help alleviate occasional symptoms, but doing 
so in the absence of a true diagnosis is not standard of care.  
 
1.5.2 COPD Evaluation: Exercise Testing 
 Cardiopulmonary exercise testing (CPET) is widely used in COPD for the 
evaluation of functional capacity and assessment of exercise tolerance and exertional 
dyspnea, which are the two most important outcomes in COPD patients [44, 45]. CPET 
typically includes measure of oxygen uptake (VO2), carbon dioxide output (VCO2), 
minute ventilation (VT) and monitoring of electrocardiography, blood pressure, heart 
rate, and oxygen saturation [44].  
 There are various protocols that can be used for exercise testing and they are 
mainly conducted on a treadmill or a cycle ergometer [44]. Tests conducted on a 
treadmill permit patients to use larger muscle mass as compared to cycle ergometry, 
which is revealed through maximal oxygen consumption (VO2) measurements [46]. 
However, the cycle ergometer is more cost efficient, requires less space, and puts less 
physical stress on patients with chronic illnesses [19]. Protocols can be classified as 
maximal or submaximal, incremental or constant loads, and self-paced or externally- 
paced [47]. Maximal exercise tests aim to measure maximal oxygen consumption (VO2 
max). However, reaching a true physiological maximum, which is challenging for healthy 
individuals, is almost impossible for COPD patients [48]. Thus, for patients with chronic 
diseases, symptom-limited or sub-maximal exercise tests (which are stopped at a pre-
determined endpoint) are often used [47]. Incremental exercise tests involve a 
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progressive increase in work rate over time (e.g. maximal incremental cycle ergometry 
and maximal incremental treadmill), whereas constant-load exercise tests consist of 
patients exercising at a fixed workload which is mainly determined by a certain 
percentage of their peak capacity (e.g. endurance shuttle walk test (ESWT) and constant 
work rate cycling) [47]. A self-paced protocol permits patients to choose their own 
intensity of exercise and allow them to stop and rest during the test (e.g. 6 minute 
walking test (6MWT)) [46]. On the other hand, an externally paced exercise test imposes 
the workload on patients (e.g. ESWT) [46].   
The maximal incremental cycle ergometry protocol is the most widely used 
exercise test in clinical practice [44, 45]. Since work rate is progressively increased 
during this test, it enables rapid achievement of diagnosis [44]. When considering 
constant-load tests, the ESWT has become well recognized, since it has shown to be 
highly responsive to treatment in COPD patients [44]. It has also been shown that ESWT 
was more likely to detect changes in COPD functional status post-bronchodilator than 
constant work rate cycling or 6MWT [49]. Since exercise tests do not exhibit the same 
responsiveness to treatment in COPD patients, it is hard to determine which protocol is 
best suited to evaluate functional capacity in this patient population [47, 50, 51].  
Various factors can affect results obtained from exercise tests such as changes 
in patient’s clinical status, symptoms, and medication(s), which are often seen in 
progressive diseases (e.g. COPD) [44]. Moreover, instructions, patient motivation, test 
procedures, equipment calibration errors and time of test conduction can affect the 
variability of the exercise test values [44]. Thus it is important to control for all these 






Although there is no cure for COPD, early detection and management are 
necessary in order to slow the progression of the disease and to improve symptom 
management [6]. Once a diagnosis is made, there are a number of secondary preventive 
measures that are important to slow progression of the disease (Figure 1.4). Patients 
with COPD should ideally be managed in an interdisciplinary environment. Interventions 
should include; smoking cessation, medication optimization, education and self-
management, pulmonary rehabilitation, oxygen therapy and in very rare cases surgery 
[3].  
 
Figure 1.4 A comprehensive approach to the management of chronic obstructive pulmonary disease 
(COPD). AECOPD Acute exacerbation of COPD; LABA Long-acting beta2-agonist; MRC Medical Research 
Council; PRN As needed; Rx Treatment [3] 
 
1.6.1 Reducing Risk Factors 
 Identifying, reducing and controlling COPD risk factors are important steps for the 
development of adequate prevention and treatment strategies [6]. These factors include 
cigarette smoking, occupational exposures, and indoor and outdoor air pollutants [6]. 
Since cigarette smoking is responsible for 80% of COPD cases, it should be regarded as 
primary and specific intervention [7]. It is of importance to evaluate smoking routinely 
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and to aid in smoking prevention and cessation at all levels of the disease [6, 7]. In fact, 
it has been shown that smoking cessation is the single most cost effective approach to 
prevent or delay airflow limitation progression linked to COPD [3, 6]. Interventions to 
prevent smoking are effective in both sexes, in all races, and at all ages [6], however a 
successful smoking cessation strategy requires a multifaceted approach. This highlights 
the importance for health professionals to offer counselling, support and education to 
COPD patients throughout the process [6]. In order to reduce exposures to fumes, 
mineral and biological dusts in the workplace, it is important to implement a legally 
mandated air control and to educate employees and employers about occupational lung 
disease in order to encourage reduction of their exposure to these various airborne 
substances [6]. Individuals exposed to diverse indoor and outdoor environment air 
pollution should reduce their risk by monitoring public announcements of outdoor air 
quality and by using adequate ventilation when cooking or heating with various solid 
fuels [6].   
 
1.6.2 Pharmacologic Treatment 
Pharmacotherapy is used in COPD patients to prevent and control symptoms, to 
reduce the frequency and severity of exacerbations, and to improve health status and 
exercise capacity [6]. Pharmacotherapy is optimal when prescribed on an individual 
basis and by assessing level of COPD severity and frequency of exacerbations [7]. 
Bronchodilators represent the fundamental pharmacological treatment for the 
symptomatic management of COPD [6, 7]. They improve expiratory flow rates and 
decrease hyperinflation by relaxing the airway smooth muscle [6, 7]. There are three 
common types of bronchodilators, which include β2-agonists, anticholinergics, and 
methylxanthines [3, 6]. Bronchodilators can have a rapid or a slow onset. Short-acting 
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bronchodilators, such as β2-agonists (e.g. salbutamol) and anticholinergics (e.g. 
ipratropium bromide) act quickly and are often used as needed, to help relieve dyspnea, 
increase pulmonary function and exercise capacity in COPD patients [3, 6]. Long-acting 
bronchodilators (e.g. salmeterol and tiotropium) take longer to act and are shown to be 
more effective and convenient than short-acting bronchodilators. Side effects associated 
with bronchodilators include tachycardia, irregular heartbeat, irritability, insomnia, and 
tremor [3, 6]. Moreover, methylxanthines (e.g. xanthenes and theophyllines), which are 
slow-onset bronchodilators administered orally, are shown to be less effective than other 
bronchodilators [6]. Methylxanthines interact with other drugs and are associated with 
some serious side effects, such as atrial and ventricular arrhythmias and grand mal 
convulsions [6].      
Inhaled and oral corticosteroids are also administered in patients with COPD [6]. 
Regular treatment with inhaled corticosteroids (ICSs) remains debatable due to its 
controversial effects regarding lung function, airway inflammation, and frequency of 
exacerbations [3, 6]. Side effects include ecchymosis, dysphonia, oral candidiasis, 
cataracts, glaucoma, pneumonia, and a decrease in bone density [3]. Oral 
corticosteroids can also be prescribed for a short or long periods of time, but there is 
insufficient evidence of their benefits [3]. Side effects related to oral corticosteroids 
include muscle weakness, decreased functionality and respiratory failure in advanced 
COPD [6].  However, combination inhaled corticosteroid/bronchodilator therapy has 
been shown to be effective in the reduction of exacerbations and in the improvement of 
pulmonary function and health-status [6].    
 Influenza vaccines can reduce about 50% of morbidity and mortality in COPD 
patients and decreases up to 39% of hospitalizations [3, 6]. Vaccines contain killed or 
live inactive viruses and are usually administered every year [6]. Pneumococal 
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polysaccharide vaccine is usually administered every 5 to 10 years and is recommended 
in older patients affected by COPD, since it is shown to decrease pneumonia incidence 
[3, 6].      
 Pharmacological treatments do not appear to decrease the rate of decline in lung 
function in COPD patients and their effect on exercise capacity, peripheral muscle 
function and quality of life remain modest [2, 3, 7, 52]  
 
1.6.3 Education and self-management 
Educating patients and their families about disease specific self-management is 
important to optimize COPD management [3]. COPD education should preferentially be 
done individually and should be specific to each patient’s disease severity [3]. Integrating 
self-management as part of the overall management of COPD has been shown to 
decrease hospital visits. The goal of self-management is to increase patients’ skills 
required to carry out medical procedures specific to their illness, to improve patients’ 
confidence in their ability to follow a self-care regimen, to encourage behavioural 
change, and to offer patients moral support to control their disease and to have a better 
health-related quality of life [53, 54]. COPD patients have perceived barriers and factors, 
which will hinder or facilitate lifestyle modification [54]. Thus, it has been shown that a 
continuum self-management program promotes self-health behaviours in COPD 
patients, which reduces use of hospital services [53, 54]. In order for self-management 
to be successful, a multifaceted approach needs to consist of disease education and 




1.6.4 Exacerbation management 
According to the Canadian Thoracic Society recommendations, exacerbations in 
COPD are defined as ‘sustained worsening of dyspnea, cough or sputum production 
leading to an increase in the use of maintenance medications and/or supplementation 
with additional medication’ [3]. COPD exacerbations worsen disease progression, 
increase cost and hospitalizations, decrease health-related quality of life and enhance 
mortality [3, 13]. Exacerbations can also cause tachycardia and tachypnea,insomnia, 
depression and confusion [6]. It is therefore important to manage and prevent 
exacerbations in the optimal care of COPD patients [3, 13]. During exacerbations, 
bacteria have been shown to be present in high concentrations in the lower airway of at 
least 50% of COPD patients. However, exacerbations can also be caused by viral 
infections, allergens or irritants, congestive heart failure, and/or pulmonary embolism [3, 
6]. Exacerbations can be categorized into simple or complicated based on the presence 
of risk factors that increase the chances of treatment failure [3]. 
 Management of exacerbations requires a careful medical history, physical 
examination and laboratory investigation (e.g. arterial blood gas) [3]. To improve 
functional capacity and to decrease dyspnea during exacerbations, an increase in the 
dose and/or frequency of short-term acting bronchodilator therapy is often prescribed 
and is sometimes combined with another bronchodilator or anticholinergic [3]. Oral or 
inhaled corticosteroids (i.e. prednisone) are often prescribed in acute COPD 
exacerbations to improve lung function and hypoxemia [6]. Corticosteroids are shown to 
shorten recovery time, reduce risk of early relapse and treatment failure [3, 6]. Antibiotics 
are administered when COPD patients experience increase in 2 of the following 
symptoms; dyspnea, sputum volume, sputum purulence [3, 6].   
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1.6.5 Oxygen Therapy 
 Oxygen therapy (OT) is shown to increase survival, improve exercise capacity, 
and enhance sleep quality and cognitive performance [6, 7]. OT is generally introduced 
in COPD patients with stage IV severity level and is usually determined by arterial blood 
gas assessment, which includes acid base information [6, 7]. Arterial oxygen saturation 
(SpO2), measured by pulse oximetry, is also a good screening tool [7]. Thus, oxygen 
therapy is usually prescribed when arterial oxygen pressure (PaO2) is less than 55 
mmHg [7].  The primary goal of OT is to increase PaO2 to 60 mmHg at rest and to 
ensure SpO2 of a minimum of 90% to ensure adequate oxygen delivery to the vital 
organs [6, 7]. Long-term oxygen therapy (LTOT) should be based on PaO2 values at the 
patient’s waking. If OT is prescribed during exacerbation, reassessment should be done 
in the following 30 to 90 days [7]. Some COPD patients only require OT during activity. 
Whatever the patient’s need is, OT prescription should include source of supplemental 
O2, method, duration, and flow rate at rest, during exercise and during sleep [6]. The 
combination of LTOT and ventilatory support can also be prescribed in selected patients 
with prominent day hypercapnia [6].   
 
1.6.6 Surgical Treatment 
Surgical treatments in COPD include bullectomy, lung volume reduction surgery, 
and lung transplantation [6, 7]. Although, COPD patients have increased risk for 
postoperative pulmonary complications, surgery is not absolutely contraindicated in this 
patient population [6, 7]. Surgery should be carefully considered and should be based on 
pre-operative thorough evaluations of pulmonary function tests [7]. In general, the further 




Bullectomy can be performed thoracoscopically and consists of removing large 
bulla to decompress lung parenchyma and alleviate infection or chest pain [6]. Prior to 
resection of the bulla, it is important to determine its effect on the lung and to evaluate a 
thoracic CT scan, arterial blood gas measurements and respiratory function tests [6]. 
Lung volume reduction surgery (LVRS) involves the resection of some parts of the lung 
to decrease hyperinflation, improve mechanical efficiency of respiratory muscles, 
increase lung elastic recoil and thus improve expiratory flow rates [6]. LVRS is expensive 
and should be carefully recommended. Lung transplantation is not only an expensive 
procedure, but it is also limited due to a lack of donor organs [6]. Many complications are 
associated with this procedure such as surgery death, acute transplant rejection, 
bronchiolitis obliterans, fungal and bacterial infections, lymphoproliferative disease, and 
lymphomas [6].    
Although risk is involved with surgery, all aforementioned surgeries aim to 
improve SpO2 values, lung volumes, exercise capacity, dyspnea, health-quality of life 
and survival in appropriately selected COPD patients [7].  
 
1.6.7 Pulmonary Rehabilitation 
The benefits attained with Pulmonary Rehabilitation (PR) are significantly greater 
compared to those obtained with pharmacological treatments [2, 52]. PR has become 
widely recognized as the best available intervention to impact on the systemic 
consequences related to COPD [52, 55, 56]. It combines exercise training, patient 
education, and psychosocial support [57]. These various strategies are integrated into 
the long-term management of COPD and require a dynamic collaboration among the 
patient, his/her family and health professionals [56]. The main goals of PR are to 
increase exercise tolerance, reduce COPD symptoms, improve health-related quality of 
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life (HRQL), and decrease the economic burden linked to this disease [57]. A meta-
analysis of 23 randomized controlled trials, comparing the effects of PR to standard care 
in patients with COPD, has shown that PR significantly improves HRQL and exercise 
tolerance and decreases dyspnea compared with conventional care [52, 58]. Studies 
have also shown the role of PR on psychological benefits in COPD patients, such as 
improved self-esteem and increased well-being which can contribute to fewer hospital 
admissions and thus decrease the economic and social burdens related to COPD [3, 59, 
60]. Although all components of PR contribute to patient’s health, exercise conditioning 
is considered the key component [2, 3].   
 
 1.7- Exercise Training in Pulmonary Rehabilitation 
1.7.1 Benefits of Exercise Training in COPD  
Although all components of PR contribute to the patient’s overall health, exercise 
conditioning is considered a key component to a successful PR program in COPD [59]. 
Exercise training has been shown to be responsible for many of the health benefits of 
PR, such as increased exercise capacity, decreased exertional dyspnea [61], and 
improved activities of daily living [59, 62]. 
The main factors limiting exercise capacity in COPD patients are dyspnea and 
skeletal muscle dysfunction [57, 63, 64]. In this patient population, the ventilatory 
requirement (or VE) of any given task is increased compared to healthy individuals due 
to increased dead space and impaired gas exchange, while ventilatory capacity is 
reduced because of mechanical constraints inflicted by the lung’s pathophysiology [56]. 
As such, COPD patients often exhaust their ventilatory reserve during incremental 
exercise and reach a ventilatory limitation, a phenomenon not typically seen in healthy 
individuals. Furthermore, peripheral muscle dysfunction, muscle wasting and weakness, 
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typical of COPD patients, all contribute to decreased aerobic capacity and poor muscle 
endurance [56, 57].  
Exercise training has been shown to reduce minute ventilation for any given 
physical effort [65], to decrease the sensation of dyspnea [61, 64], and to improve 
peripheral and respiratory muscle strength [66] as well as oxidative capacity [59, 62]. 
These physiological mechanisms mediated by exercise training lead to improved 
maximal oxygen consumption (VO2max), peak work rate, and endurance time to 
constant-load exercise in this population [66, 67]. It has also been shown that exercise 
training has a positive effect on motivation, mood, self-esteem, and general well-being 
[56, 60]. There is also evidence that exercise has a positive acute effect on cognitive 
performance in COPD patients [68]. These benefits have a great impact on the daily 
lives of COPD patients’ by increasing their ability to perform normal routine tasks and 
recreational activities [67]. Although physical exercise is a main component of PR and is 
greatly beneficial, there is an ongoing debate about the type and intensity of exercise 
that should be prescribed to COPD patients (Table 1.2) [62, 69].  
 
1.7.2 Intensity and Types of Training   
1.7.2.1 High-Intensity Exercise:  
Current guidelines recommend high-intensity exercise, which was shown to elicit 
greater physiological adaptation as compared to low-intensity exercise in COPD patients 
[65]. However, the evidence favouring high-intensity over moderate- or low-intensity 
training in this patient population is limited. In fact, the guideline encouraging high-
intensity training is based on one small (n=19) randomized clinical trial, in which the 
physiological adaptation to a high training work rate ( 80% of peak work rate) was 
compared to that of a low training work rate ( 50% of peak work rate) [65]. At the end of 
30 
 
the program (week 8), the high-intensity exercise was shown to elicit a greater 
physiological training response (decreased lactate levels and minute ventilation for a 
given work rate) and higher exercise tolerance and was therefore considered optimal 
[65]. Moreover, although some studies have shown that high-intensity training can be 
tolerated by patients with moderate to severe COPD [70, 71], a major concern remains 
with the ability for patients to remain compliant to this type of intensity [52, 69, 72]. A 
study by Maltais et al., consisting of a 12-week exercise program, has shown that high-
intensity training was only achieved by 0, 3, 5 and 5 patients out of 42 at weeks 2, 4, 10, 
and 12 respectively [69]. In light of this potential compliance issue related to continuous 
high-intensity training, other approaches to exercise training have been proposed.  
 
1.7.2.2 Exercise at the Ventilatory Threshold:  
The ventilatory threshold is described as the breakpoint during progressive 
exercise above which minute ventilation increases disproportionately to increments in 
oxygen consumption [73]. The ventilatory threshold differs for each person and therefore 
needs to be determined individually with an incremental exercise test.  Exercising at the 
ventilatory threshold is associated with tolerable levels of ventilation and dyspnea, which 
represent two of the main exercise limiting factors in patients with COPD [73, 74]. The 
efficacy of training at the ventilatory threshold versus training at a standardized 
moderate intensity (50% of heart rate reserve) has been studied in 24 patients with 
moderate COPD [73]. Although the mean training intensity was similar for both groups, 
training at the ventilatory threshold led to better physiological responses (greater 
reductions in lactate levels, CO2 excretion, and minute ventilation for a given workload) 
than training at 50% of heart rate reserve [73]. This training approach has also been 
shown to improve peripheral muscle strength and endurance [75]. However, no study 
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has yet compared the short-term compliance of training at the ventilatory threshold 
versus training at 80% of peak work rate. 
 
1.7.2.3 Interval Training: 
Interval training (IT) has recently been established as an alternative modality to 
continuous training in PR [55] and consists of alternating bouts of maximal or high-
intensity exercise with short periods of rest or active recovery [56, 64, 72, 76, 77]. 
Interval exercise is most consistent with patterns of activities of daily living in severe 
COPD patients [55].  
The physiological responses to a single IT session were compared to those of 
continuous training at the same absolute workload (70% of peak workload) in 10 patients 
with moderate COPD [72]. In this study, IT, which consisted of 1 minute of exercise 
interspersed with 1 minute of rest, has shown to induced lower levels of ventilation, lung 
hyperinflation and dyspnea when compared to continuous training and enabled subjects 
to perform a greater total amount of work [72]. In a randomized non-inferiority trial 
conducted by Puhan and colleagues [78], which included 98 patients with severe COPD, 
showed that interval exercise is as beneficial as high-intensity continuous exercise in 
improving HRQL and exercise capacity. Furthermore, Vogiatzis et al. [77] have 
demonstrated that high intensity interval training and moderate intensity constant-load 
exercise caused similar peripheral muscle adaptation (increased oxidative capacity, 
increased lactate threshold), however interval training was associated with lower 
dyspnea and leg discomfort levels in COPD patients. Finally, Coppoolse and colleagues 
[55] compared continuous training with a mixed programme of interval and continuous 
training and found that peak workload increased only with mixed training while 
improvement in peak oxygen uptake was observed only with continuous training. 
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Although, various studies have shown controversial findings, interval training is still 
considered an adequate alternative for patients who are unable to achieve the 
prescribed exercise time or intensity [56].   
 















IT: cycling at 70% of Ppeak (1 min) 
and rest (1min) (total duration 
60min);  
 
CT: cycling at 70% Ppeak (total 
duration 30min) 
IT: ↓ lower levels of 
ventilation, ↓ lung 
hyperinflation and ↓ 
dyspnea  and ↑ total 






IT: cycling at 90% of Ppeak (1min) 
and 45% of Ppeak (2min) 3 
days/week;  
 
CT: cycling at 60% Ppeak 2 
days/week 
 
IT and CTsimilarly 









IT: cycling at 100% Ppeak (30sec) 
and 45% Ppeak (30sec) weeks 1-3; 
at 120% weeks 4-6 and 140% 
weeks 7-10;  
 
CT: Cycling at 60% Ppeak weeks 1-
3 at 70% Ppeak weeks 4-6 and at 
80% weeks 7-10 
 
High intensity IT and  
CT: ↑ oxidative 
capacity, ↑ lactate 
threshold;  
 









IT: cycling at 90% of Ppeak (1min) 
and 45% of Ppeak (2min) 3 
days/week plus continuous 
cycling at 60% Ppeak 2 days/week;  
 
CT: cycling at 60% of Ppeak  
 
Mixed training (IT + 
CT): ↑ peak workload;  
 
CT: ↑peak oxygen 
uptake 
COPD: Chronic Obstructive Pulmonary Disease; IT: Interval training; CT: Continuous training; Ppeak: peak 
exercise capacity.  
 
1.7.3 What is the Optimal Exercise Prescription? 
To date, no controlled study has yet been designed to define optimal duration or 
frequency of training sessions in PR. Current guidelines regarding session duration are 
based on evidence obtained in healthy individuals [79], while recommendations for 
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frequency of training sessions stem from clinical trials of PR versus usual care that were 
not designed to determine optimal training dose [80, 81]. Thus, the optimal exercise 
prescription (training mode, intensity, and duration) remains undetermined for patients 
with COPD, which explains the ambiguity of current guidelines for exercise training in 
PR. In their 2006 statement on PR [56], the American Thoracic Society and European 
Thoracic Society made the following recommendations with regards to the exercise 
dose: “A minimum of 20 sessions should be given at least three times per week to 
achieve physiologic benefits; twice-weekly supervised plus one unsupervised home 
session may also be acceptable. High-intensity exercise produces greater physiologic 
benefits and should be encouraged; however, low-intensity training is also effective for 
those patients who cannot achieve this level of intensity. […] The total effective training 
time should ideally exceed 30 minutes. However, for some patients, it may be difficult to 
achieve this target training time or intensity, even with close supervision. In this situation, 
interval training may be a reasonable alternative”. In summary, current guidelines for PR 
suggest high-intensity exercise training to elicit greater physiological benefit. However, 
compliance to this type of training has been problematic for COPD patients. Thus, 
alternative approaches (i.e. ventilatory threshold and interval training) have been 
proposed as more tolerable, and possibly easier to comply with, but the compliance to 
these different exercise-training approaches has yet to be examined in COPD patients. 
 
1.8- Compliance to Exercise Training 
1.8.1 Definition of compliance 
Compliance was first defined by Haynes et al. [82-84] in 1979 as “the extent to 
which a person’s behaviour (in terms of taking medications, following diets, or executing 
lifestyle changes) coincides with medical or health advice”. The term ‘compliance’ is 
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exclusive to the conformity of medical goals [85] and is often interpreted as an 
authoritarian word, suggesting patients’ obedience to instructions given by health care 
professionals [83, 85]. Because of its dictator tone, the term ‘compliance’ began to be 
interchangeably used with the term ‘adherence’ [83]. ‘Adherence’ characterizes patients 
as independent and autonomous individuals who voluntarily pursue their goals to follow 
their medical treatment [85]. The popularity of this term increased with modern era, 
where patients’ rights not to follow medical advice were acknowledged and practitioners’ 
attention to patients’ decision-making processes related to their health was recognized 
[82, 83, 85]. Thus, it is clear that some critical differences between the terms 
‘compliance’ and ‘adherence’ are present [85]. Hence, for the purpose of this study, we 
will solely use the term ‘compliance’.    
 
1.8.2 Factors affecting Exercise Compliance 
Despite the increased knowledge and proven benefits of exercise training, only 
about 15% of Canadian adults meet the new physical activity guidelines [86, 87]. To 
achieve health benefits, the World Health Organization and Canadian guidelines 
recommend that adults accumulate a minimum of 150 minutes of moderate-to high-
intensity aerobic exercise per week [87]. In Canada, the proportion of adults over 65 
years of age is growing rapidly and represents the most sedentary portion of the 
population [86]. Research suggests that 49% of older adults who enrol in community 
exercise programs will drop out within one-year of starting the program [86]. Hence, the 
importance for health professionals to be aware of and to understand the various 
variables influencing the initial adoption and long-term maintenance of exercise training 
patterns [88]. In fact, factors such as behavioral, personal, environmental, program-
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related, and self-efficacy elements need to be taken into consideration when looking at 
exercise compliance rates and success of therapeutic regimens [88].       
 
1.8.2.1 Behavioural factors : 
Behavioural factors, such as behavioural shaping, goal setting, enjoyment, 
intrinsic and extrinsic reinforcement, social support, behavioural success, self-
monitoring, and self-management, are considered important when eliciting initial 
adoption of exercise.  Gradual shaping or progression of the exercise-training program 
towards the individual’s goal is a key consideration [88]. Shaping behavioural success is 
influenced by realistic goal settings and based on principles that are specific, 
measurable, realistic, and time specific [88]. Thus, individuals are more likely to 
successfully achieve their goals if they are realistic and motivationally challenging [88]. 
Moreover, the individual’s motivation to continue exercise training and adopt a healthy 
lifestyle depends on the rewards and the degree of enjoyment coming from the new 
behaviour [88]. Enjoyment and perceived improvement of any activity play a significant 
role for patients PR maintenance [89]. On the other hand, longer periods of inactivity are 
negatively associated to intrinsic reinforcements [88]. In fact, the more unfit the individual 
is or becomes, the more time it will take before any exercise training becomes reinforced 
(e.g. feels good to exercise) [88]. It is therefore important for patients to receive extrinsic 
rewards (motivation, encouragement) and social support (e.g. from health professionals 
and family members) to help ensure their behavioural change success and their 
compliance to exercise [88, 89]. Other ways of establishing behavioural success include: 
monitoring attendance and adherence, engagement and performance in exercise 
training programs, and integration of exercise habits [88]. In addition, behavioural factors 
incorporate the skills to carry out and comply with physical activity to facilitate health 
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benefits while avoiding injury or boredom. In summary, patient exercise compliance can 
be achieved by setting realistic goals, engaging in enjoyable activity, and encouraging 
and motivating good health behaviours [88]. 
 
1.8.2.2 Personal factors :  
Personal health factors have been shown to be directly related to levels of 
physical activity [88]. In fact, older individuals with medical disabilities, such as COPD, 
have a higher risk of adopting a sedentary lifestyle [88]. Cognitive and experiential 
variables, such as bad experiences, a low level of enjoyment with physical activity, and 
degree of self-motivation can all negatively influence exercise initiation and participation 
[88]. Certain life events such as recurrent exacerbations, admission to hospital, and 
family health problems [90] can make exercise compliance very challenging. Another 
key factor affecting patients’ willingness to partake in exercise programs is the level of 
understanding regarding their illnesses and the personal benefits that they could achieve 
with physical activity [82, 88]. Thus, COPD patients having the internal desire for 
achievement may increase their readiness to start and pursue exercise regimens [88]. 
Self-motivation can be achieved when individuals are capable of identifying self-related 
rewards for their behaviour [88]. Finally, targeting each person’s interests and goals, 
stressing the beneficial outcomes of exercise training, and exploring perceived barriers 
can all positively influence exercise habits [88].    
 
1.8.2.3 Environmental factors : 
Several environmental factors have an impact on the initiation and maintenance 
of an exercise program, such as proximity and affordability of facilities, time constraints, 
weather, social (family support), and physical environment (sidewalks, street-lights) [88]. 
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A study conducted in the UK has shown that poor attendance is associated to the 
distance between the patient’s home and PR location and is often related to 
transportation difficulties [90]. It is, therefore, important to carefully evaluate the proximity 
of exercise programs in order to minimize the negative factors leading to exercise non-
compliance [88]. 
 
1.8.2.4 Program-related factors: 
Adequate attendance and compliance are necessary to gain benefits from PR 
programs [90] and it has been shown that the type, intensity, duration, and frequency of 
the exercise programs are important factors influencing the levels of participation [88]. It 
is therefore important to consider program-related factors to prevent risks of aversive 
sensory and physiologic consequences [88] and to reduce their negative effect on 
exercise compliance.  
Compliance to the type of exercise:  
In relation to program-related factors, Mador et al. [91] have shown that it is easier for 
elderly patients with COPD to perform high-intensity training on a cycle ergometer than 
on a treadmill. In fact, this study revealed that this patient population had a lower 
compliance rate to high-intensity training on a treadmill when compared to a cycle 
ergometer, due to the difficulty in maintaining the required speed. Additionally it was 
shown that there was a higher risk of fall [91].  There is also evidence supporting interval 
training over continuous training [72], where interval training has been associated with 
reduced breathlessness, longer periods of exercise, and greater total amount of work in 
COPD patients [52, 72, 92]. In Puhan et al.’s study, where IT was compared to high-
intensity CT, tolerance to the protocol was compared by looking at the number of 
unintended breaks of ≥ 1 minute and at the proportion of patients achieving the target 
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intensity, as assessed via continuous data tracking technology [78]. Interval training was 
found to be associated with significantly fewer unintended breaks and with better 
compliance to the IT protocol than continuous high-intensity training (48% versus 24%, 
respectively) [78]. Interval training is believed to lead to an increased compliance to the 
exercise regimen compared to continuous training [52, 72], hence the importance of 
prescribing the adequate type of exercise training to specific populations.  
Compliance to the intensity of exercise: (high versus low) 
When individuals, especially sedentary ones, are initiated to exercise programs 
that are often too high in intensity, there is an increased chance for non-compliance due 
to aversive sensory and physiologic consequences [88]. In fact, high-intensity exercise 
regimens have been associated with decreased exercise compliance rates, since this 
exercise intensity is often linked to increased cardiovascular and orthopedic problems in 
elderly patients [79, 88]. Moreover, although high-intensity (80% of peak work rate) 
exercise regimens are shown to be feasible in some COPD patients [65], the majority of 
moderate to severe COPD patients can hardly tolerate this exercise intensity [56, 69].  
Compliance to the duration and frequency of sessions: 
Several studies have compared exercise compliance rates in COPD patients 
between a short-term (3 or 6 weeks) and a long-term (18 weeks) exercise rehabilitation 
program [90, 93]. A study comparing short and long-term effects of outpatient 
rehabilitation has shown that 31% of participants have dropped out of the study by 6-
months and that this drop-out rate increased to 36% by 18-months of the program [66]. 
Another study has shown that mean exercise frequency is greatest in the early weeks of 
rehabilitation programs and decreased linearly throughout a 12 month home-walking 
exercise prescription in COPD patients [94]. These findings were similar to that of 
Soicher et al. who found a decrease in adherence to physical exercise following PR [95]. 
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In fact, at 1 and 12 months following completion of PR, patients’ adherence rate to 
endurance training was 61% and 46% respectively [95]. These studies have shown that 
mean attendance tended to be higher in short-term compared to long-term programs 
[90, 93]. This may be explained by the patients’ loss of motivation, failure to develop a 
group identity and increasing likelihood to develop exacerbations and hospitalization 
over time when attending longer duration PR programs [90, 94]. Supervision is however 
vital as the duration (expressed in minutes) of activity is shown to increase with time in 
patients that are supervised during their exercise sessions and decrease in those who 
exercise without supervision [94]. 
 
1.8.2.5 Self-Efficacy : 
In 1970s, Bandura developed the Social Cognitive Theory (SCT), which is also 
known as the Social Learning Theory [96]. This theory states that behaviour change is 
influenced by complex interactions between the individual, the environment, and the 
behaviour [97]. One of the main components of Bandura’s SCT is self-efficacy [98]. The 
SCT construct of self-efficacy explains how individual perceptions of ability affect 
behaviour, level of motivation, thoughts, and emotional reactions [99]. Self-Efficacy 
investigates an individual’s emotional function and coping skills required to deal with a 
particular situation [100, 101]. Self efficacy is developed from four primary experiences: 
performance accomplishments (achieving mastery over a task through personal 
experience), verbal persuasion (using strong verbal encouragement regarding the 
behaviour benefits and individual’s progress), social modelling (observing success of 
others), and emotional arousal (reassuring individual’s response to the effects of the 
behaviour) [99, 102].  
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COPD results in dyspnea and patients develop a lack of confidence in their 
capacity to perform certain tasks, which leads to decreased activity of daily living and 
quality of life [101]. Some of the important aims of PR are to increase confidence, 
improve physical capacity, and enhance self-management ability in patients suffering 
from COPD [100]. Self-efficacy has been shown to be a determinant of exercise 
adherence and it has been identified as being a fundamental aspect in patients’ ability to 
manage their own disease [97, 100]. This highlights the importance of focusing on self-
efficacy in the treatment of COPD [100].  A recent study by Bentsen et al. [101], has 
shown that higher levels of self-efficacy in COPD patients at baseline is a good predictor 
of increased health status and quality of life, and improved psychosocial function after 
completion of PR.  Moreover, it has been shown that increasing self-efficacy positively 
influences health behaviors, which in turn impacts the effects of PR on clinical and 
functional outcomes [97, 100]. In fact, higher self-efficacy levels have been related to PR 
completion and success, and exercise compliance and maintenance [97, 100-102]. It 
has also been shown that participation in a PR program could in turn enhance self-
efficacy levels regarding self-management and control of dyspnea in COPD patients 
[102]. Studies have shown that multifaceted PR programs have a great impact on 
patients’ self-efficacy by incorporating performance accomplishment, vicarious 
experiences, verbal persuasion and control of emotional/physical arousal [98, 102]. In 
addition, increase in compliance with an exercise program was associated with 
enhanced expectations to perform this type of exercise in the future [98]. Thus, self-
efficacy plays an important role in exercise compliance and has the advantage of making 































Rational and Clinical Significance 
PR is currently considered the best available intervention to impact the systemic 
consequences of COPD.  Current PR guidelines advocate high-intensity exercise 
training (at  60-80% of peak work rate) for COPD patients. However, the compliance to 
this type of training has been problematic in this patient population. Alternative 
approaches to exercise training in COPD patients, including training at the ventilatory 
threshold and interval training, have been proposed as more tolerable, less unpleasant, 
and thus possibly easier to comply with, but this assumption remains to be verified. To 
our knowledge, no study to date has directly compared these three different exercise-
training protocols (high-intensity training, ventilatory threshold training, and interval 
training) to determine which one, if any, best ensures patient compliance.  
The general aim of the present randomized clinical trial [103] was thus to 
compare patient compliance between these three exercise-training protocols in 
individuals with COPD. Clinically, this research project will improve our understanding of 
exercise compliance in COPD and the main role that it plays in the optimization of the 
benefits derived from a PR program. Given that exercise compliance is essential to the 
effectiveness of PR and that, without it, no therapeutic goal can be achieved, findings 
from this study are expected to contribute significantly to future PR clinical practice 






























Research Objectives and Hypotheses 
The purpose of the present study was to compare the 12-week compliance rates 
to the following three exercise-training protocols: 1) continuous training at high-intensity 
(CTHI), 2) continuous training at the ventilatory threshold (CTVT), and 3) interval training 
(IT) in patients with moderate to severe COPD. More specifically, the primary objective 
of this research was to compare compliance to the three training protocols by measuring 
the attendance rate and the compliance rate to the prescribed intensity during the 12-
week program. The secondary objective was to examine the relationship between 
exercise compliance and baseline self-efficacy scores in patients with COPD.  
The research hypotheses were as follows: 1) patient compliance will be highest 
in the CTVT group, followed respectively by the IT group and the CTHI group; and 2) a 




































Compliance to Different Exercise-Training Protocols in Individuals with 
Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial  
Primary Author 
Rima Wardini, B.Sc., rimawardini@gmail.com 
Co-Authors 
Amanda K. Rizk, ak_rizk@gmail.com 
Emilie Chan-Thim, e.chanthim@gmail.com 
Barbara Trutschnigg,b.trutsc@gmail.com 
Amélie Forget, amelie.forget@umontreal.ca 
Grégory Moullec, gregory.moullec@crhsc.rtss.qc.ca 
Véronique Pepin, v-pepin@crhsc.rtss.qc.ca 
 
Institution 
Axe de recherche en maladies chroniques, Hôpital du Sacré-Coeur de Montréal 
 
Rima Wardini, B.Sc. (Kinesiology) Hôpital du Sacré-Coeur de Montréal, master’s 
student, Department of Exercise Science, Concordia University. 
 
Amanda K. Rizk, M.Sc. (Kinesiology) Montreal Behavioural Medicine Centre, Hôpital du 
Sacré-Coeur de Montréal, PhD student, Department of Exercise Science, Concordia 
University. 
 
Emilie Chan-Thim, M.Sc. (Kinesiology) Hôpital du Sacré-Coeur de Montréal, PhD 
student, Department of Exercise Science, Concordia University. 
 
Barbara Trutschnigg, M.Sc. (Kinesiology) Hôpital du Sacré-Coeur de Montréal. 
 
Amélie Forget, (Research assistant) Hôpital du Sacré-Coeur de Montréal  
 
Grégory Moullec, Ph.D. (Health Psychology) Hôpital du Sacré-Coeur de Montréal.   
 
Véronique Pepin, Ph.D. (Kinesiology), Montreal Behavioural Medicine Centre, Hôpital 





Rationale: Current guidelines for pulmonary rehabilitation suggest high-intensity 
exercise training for patients with chronic obstructive pulmonary disease (COPD). 
However, compliance to this type of training is problematic. Alternative approaches, such 
as training at the ventilatory threshold and interval training, have been proposed as 
easier to comply with. The objectives of this study were to: 1) compare patient 
compliance to three exercise-training protocols: continuous training at high-intensity 
(CTHI), continuous training at the ventilatory threshold (CTVT), and interval training (IT); 
2) determine if a relationship exists between exercise compliance and baseline self-
efficacy in COPD patients. Methods: Subjects were randomly assigned to one of the 
protocols and trained on a cycle ergometer three times per week for 12 weeks. 
Compliance to the training protocol was measured by attendance and compliance rates 
to the prescribed intensity. Compliance data were obtained through data tracking 
technology allowing second-by-second recording of exercise-training sessions. Self-
efficacy was measured using the Self-Efficacy Scale. Results: Thirty-six subjects with 
moderate to severe COPD participated in the study. Attendance rates did not differ 
significantly between groups (Mean  SD: 70  33% for CTHI, 82  17% for CTVT, 63  
35% for IT, p= 0.229). Mean compliance rates were 85.6 ± 15.0 % for CTHI, 84.1 ± 15.1 
% for CTVT, and 52.0 ± 41.8 % for IT (p=0.07). Self-efficacy did not correlate with mean 
attendance or mean compliance to the prescribed intensity. Conclusion: The present 
study suggests that IT may be associated with lower compliance rates than CTHI and 
CTVT. 




COPD is the fourth leading cause of mortality in the world and in Canada and it 
represents a major cause of respiratory morbidity [6, 9, 10]. COPD is characterized by 
chronic airflow limitation, chronic respiratory symptoms and declining functional status 
and quality of life [2, 6, 9]. In 2004, COPD was responsible for 9,607 deaths in Canada 
[3, 9]. More then 750, 000 Canadians are diagnosed with COPD, but the actual 
prevalence is thought to be higher [3, 9] as COPD is often under diagnosed [2, 3, 9]. The 
prevalence of the disease is likely to increase due to continued exposure to cigarette 
smoke and other potential COPD risk factors and to the aging of the population [6, 9, 
10]. COPD is a major respiratory illness exerting serious economic and social burden in 
Canada accounting for approximately $4 billion of total health care costs in 2010 [17] 
The rise in this chronic illness necessitates the expansion of existing services (primary 
care, hospital) as well as a comprehensive approach to its management [6].  
PR has become widely recognized as the best available strategy to tackle the 
systemic consequences of COPD [52, 55, 56]. It combines exercise training, patient 
education, and psychosocial support [57]. These various approaches are integral to the 
long-term management of COPD and require a dynamic collaboration among the 
patient, his/her family and the health care team [56]. Although all components of PR 
contribute to benefit patients’ overall psychological and physical health, exercise 
conditioning is considered the key element [2, 3].  
Exercise training is a mandatory component to a successful PR program in 
patients with COPD [59]. In fact, exercise training is responsible for many of the health 
benefits related to respiratory rehabilitation, such as increased exercise capacity, 
decreased exertional dyspnea [61], and improved activities of daily living [59, 78]. The 
optimal exercise-training prescription (mode, intensity, and duration) remains 
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undetermined for patients with COPD. Current PR guidelines suggest high-intensity 
exercise training to elicit greater physiological adaptation [65]. However, it has been 
shown that although high-intensity exercise regimens can be feasible in some COPD 
patients [65], the majority of moderate to severe COPD patients can hardly tolerate this 
exercise intensity [56, 69]. Therefore, alternative approaches have been proposed, such 
as training at the ventilatory threshold and interval training. The ventilatory threshold is 
described as the breakpoint during progressive exercise above which minute ventilation 
increases disproportionately to increments in oxygen consumption [73]. The ventilatory 
threshold typically occurs at 50 to 60 % of VO2 peak in the elderly, but it remains a 
parameter that needs to be determined on an individual basis [105]. Exercising at the 
ventilatory threshold is associated with tolerable levels of ventilation and dyspnea, which 
represent two of the main exercise-limiting factors in patients with COPD [73, 74]. 
Interval training consists of alternating bouts of maximal or high-intensity exercise with 
short periods of rest or active recovery [56]. There is evidence supporting interval 
training over continuous training in COPD patients [72], where interval training has been 
associated with reduced breathlessness and lung hyperinflation, longer periods of 
exercise, and greater total amount of work [52, 72, 92]. For the above mentioned 
reasons, training at the ventilator threshold and interval training have been proposed as 
more tolerable and thus easier to comply with for this patient population [73, 74]. Yet, 
this assumption needs to be verified. 
Many factors, including behavioural, personal, environmental, and program-
related factors, are important to consider when studying compliance to exercise training. 
Self-efficacy, a behavioural factor [97, 100], has been identified as a fundamental aspect 
in patients’ ability to manage their own disease and as a determinant of exercise 
adherence [97, 100]. Self-Efficacy investigates an individual’s emotional functioning and 
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coping skills to deal with a particular situation [100, 101]. A recent study by Bentsen et 
al. [101] has shown that higher levels of exercise self-efficacy at baseline was a good 
predictor of improved health status, quality of life, and psychosocial function after 
completion of PR in COPD patients. This highlights the importance of considering self-
efficacy in the treatment of COPD [100]. Moreover, it has been shown that increasing 
self-efficacy with disease management programmes positively influences health 
behaviours [97], which in turn is likely to further impact the effects of PR on clinical and 
functional outcomes [97, 100]. Higher self-efficacy levels in COPD patients have been 
found to be a good predictor of improved exercise capacity and psychosocial function in 
relation to PR [101] and is a key component in translating PR completion and success 
[100, 102].  
The general aim of the present study was to determine the optimal exercise-
training program to tackle the compliance issue often seen in COPD patients. More 
specifically, the primary objective was to compare, in individuals with COPD, the 12-
week compliance to the following three exercise-training protocols: continuous training at 
high-intensity (CTHI), continuous training at the ventilatory threshold (CTVT), and 
interval training (IT). The secondary objective was to examine the relationship between 
exercise compliance and baseline self-efficacy scores in patients with COPD. The 
research hypotheses were the following: 1) patient compliance will be highest in the 
CTVT group, followed respectively by the IT group and the CTHI group; and 2) a 








Study Design and Procedure 
The present study was a sub-study to a larger randomized, parallel-group, 
clinical trial (RCT) comparing the short-and long-term effects of different exercise 
training protocols on various PR program outcomes in COPD. As part of the larger RCT, 
patients who met the eligibility criteria and accepted to participate completed a thorough 
baseline evaluation and were then randomly assigned to one of three exercise training 
protocols: continuous training at high-intensity (CTHI), continuous training at the 
ventilatory threshold (CTVT), and interval training (IT). Subjects from the three 
subgroups trained three times per week for 12 weeks, for a total of 36 exercise sessions. 
Session duration was adjusted such that the total amount of work performed per session 
was comparable across the three protocols (Figure 4.1). Outcome assessors were 
blinded as to subjects’ group assignment. 
 
Subjects and Eligibility 
Subjects were recruited from l’Hôpital du Sacré-Coeur de Montréal and 
participated to this pilot study between May 2009 and November 2011. 
Inclusion/exclusion criteria were as follows. Inclusion: 1) clinically stable COPD; 2) age 
40 years or older; 3) smoking history of at least 10 American pack-years (20 cigarettes 
per pack); 4) post-bronchodilation forced expiratory volume in one second (FEV1) less 
than 80% of the predicted normal value; and 5) FEV1 to forced vital capacity (FVC) ratio 
less than 0.7. Exclusion: 1) exacerbation of respiratory symptoms in the past 4 weeks 
(change in dyspnea or volume/colour of sputum, need for antibiotic treatment, or need 
for hospitalization); 2) any contraindication to exercise based on guidelines from the 
American Thoracic Society (Appendix C) [106]; 3) any active condition other than COPD 
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that can influence exercise tolerance (asthma, unstable coronary heart disease, 
congestive heart failure, neoplasia, severe intermittent claudication, severe arthritis, 
etc.); 4) the need for oxygen therapy; 5) participation in a PR program in the past year; 
and 6) inability to complete baseline evaluations (including the achievement of a 
ventilatory threshold on the incremental cycling exercise test). These eligibility criteria 
were meant to differentiate COPD from other respiratory diseases and ensure clinical 
stability and patient safety. 
Randomization 
Patients were randomized to CTHI, CTVT, or IT in groups of six. Randomization by 
group (rather than individually) was selected for feasibility and contamination concerns. 
Subjects from the same group trained in the same room at the same time; this approach 
enabled us to optimize the human resources needed for supervision, while respecting 
the staff/patient ratio recommended (1/8). Randomizing subjects who trained together 
into the same intervention arm ensured that no contamination occurs between more 
demanding and less demanding protocols. Randomization of groups of six subjects was 
achieved in block, once all six subjects completed baseline assessments. The 
randomization process consisted of a computer-generated random listing of the three 
treatment allocations blocked by groups of six. 
Exercise Training Intervention 
 The exercise training bouts were performed on calibrated cycle ergometers (Bike 
Med, TechnoGym, Italy) at the hospital’s cardiopulmonary rehabilitation center (Centre 
de réadaptation cardio-respiratoire Jean-Jacques-Gauthier). Patients trained at a 
prescribed intensity and duration and at a frequency of three sessions per week for a 
total of 12 weeks. Sessions included a 10-minute warm-up, a training phase at the target 
intensity, and a 5-minute cool-down. CTHI consisted of pedalling for 25 minutes at the 
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HR reached at 80% of peak workload during the symptom-limited test; CTVT consisted 
of training at the HR reached at the ventilator threshold; and IT consisted of 30-second 
intervals at the HR reached at 100% of peak workload interspersed with 30-second of 
unloaded pedalling  IT was based on Vogiatzis and colleagues [64] method in a 
reasonable sample (n = 36) and was shown to be as effective as continuous exercise 
training at a moderate intensity. Session duration for CTVT and IT was adjusted for each 
subject using metabolic equations, such that the total amount of work performed was 
comparable to 25 minutes of CTHI. This approach has been used successfully in the 
past to isolate the effect of training intensity from that of total training dose [65]. 
 Patients were asked to train within  5 beats/min of their target heart rate, which 
was detected continuously throughout their workout by a HR transmitter (T31, Polar, 
Finland). Since heart rate response at a given submaximal workload decreases as 
cardiorespiratory fitness increases, this approach ensures that patients remain at the 
same relative (versus absolute) training intensity throughout the program. Patients also 
performed upper and lower-extremity strength training, stretching, and relaxation 
exercises. These components were standardized and identical for all groups. Overall, 
exercise sessions lasted 2-2.5 hours, including cycling (45-60 min), strength training (30 
min), stretching (10 min), and relaxation exercises (20 min). 
 Supervision was provided by trained clinical exercise physiologists (CEPs) at a 
ratio of 2 healthcare practitioners per 6 patients, which exceeds the minimum ratio of 1:8 
recommended by current guidelines [56]. Patient instructions and encouragements were 
standardized throughout the exercise training intervention since encouragement to the 
patient has been shown to have a significant effect on exercise performance [107]. 
CEPs all had basic cardiopulmonary resuscitation (CPR) training and followed the 
emergency procedures outlined for the building (YMCA-Cartierville) and those for the PR 
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program. As per current exercise training guidelines [79], patients were asked to follow a 
list of recommendations before each exercise session, including no smoking within the 
previous 2 hours, no drinking of caffeinated beverages and alcohol 2 hours before 
exercising, avoiding food for one hour or less prior to the exercise session, and taking 
their medications as prescribed. 
 
Measurements 
Baseline Measurements  
The following baseline measurements were used to characterize the sample and 
to examine potential associations with exercise compliance: demographic and clinical 
information, pulmonary function, exercise capacity, and exercise self-efficacy. Details 
regarding these measurements are provided below. 
Demographic and Clinical Information 
Basic demographic and clinical information were collected at baseline and 
include age, sex, ethnicity, and measured height and weight (for body mass index 
calculation).  
Pulmonary Function 
Spirometry, lung volumes, and lung diffusion capacity for carbon monoxide 
(DLCO) obtained at the time of enrolment. Pulmonary function tests were performed 
according to recommended techniques [106] and values were compared to predicted 
normal values from the European Community for Coal and Steel/European Respiratory 
Society [108]. 
Exercise Capacity 
Exercise capacity was obtained from a symptom-limited incremental cycling 
exercise test. This test was performed at baseline to rule out the presence of 
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cardiovascular co-morbidities and to determine the work rate at peak effort and at the 
ventilatory threshold for subsequent exercise prescription. Subjects were seated on an 
electromagnetically braked cycle ergometer (Ergoselect 200P, Ergoline, Germany) and 
connected to a 12-lead electrocardiogram (Jaeger Oxycon Pro, CareFusion, Germany) 
and to a respiratory circuit through a mouthpiece. The respiratory circuit consisted of a 
digital volume sensor (TripleV), O2 and CO2 analyzers, and a mixing chamber. After five 
minutes of rest and three minutes of unloaded pedalling, the workload was increased in 
a stepwise manner up to the individual’s maximal capacity. Each step lasted one minute 
and increments of 5-10 watts were used (5-watt increments for subjects with a predicted 
work rate < 50 watts; 10-watt increments for those with a predicted peak work rate > 50 
watts). This protocol is frequently used in standard practice [109]. Gas exchange 
parameters (minute ventilation, O2 uptake, CO2 excretion) and heart rate were measured 
at rest and during exercise on a breath-by-breath basis. Dyspnea and leg fatigue were 
evaluated at rest and every other minute during the test with the modified 10-point Borg 
scale [110]. The ventilatory threshold was determined using the V-slope method [111], 
an approach to identify the breakpoint in the VCO2-VO2 relationship. Exercise capacity 
was defined as the highest work rate maintained at a pedalling speed of at least 50 
revolutions per minute for a minimum of 30 seconds. Laboratory temperature (22.2 ± 
0.6ºC) and humidity (37.6 ± 14.6%) were maintained within recommended ranges for all 
tests. Instructions given to participants followed ACSM guidelines (ref), encouragement 
during the test was standardized, and all tests were conducted by the same 2 CEPs.  
 
Exercise Compliance and Adherence Measurements 
In the present study, the term ‘compliance’ was used to refer to the degree to 
which a patient’s behaviour concurs with instructions from a health care practitioner. 
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As such, in the present study, exercise compliance was assessed by measuring i) 
attendance to the 12-week PR program and ii) compliance to the prescribed training 
intensity from baseline to week 12. 
Attendance 
Patients’ attendance was taken at the beginning of every training session by one 
of the healthcare practitioner supervising the session. Attendance rate was computed as 
the percentage of sessions attended over the possible total of 36 sessions. If a patient 
missed a session, the data was not imputed 
Compliance to the prescribed intensity  
Compliance to the prescribed intensity was measured through new technology 
from Technogym (Italy), which is composed of special hardware (Bike Med 700 CE-R 
LED, Polar heart rate monitor, and computer) and software (CardioMemory software 
package) and allows second by second tracking of each individual exercise session 
[112]. More specifically, the CardioMemory software package records level of intensity 
(1-30), workload (Watts), pedalling speed (revolutions/minute), distance (km), pace 
(mm:ss/km), heart rate (beats/minute), estimated oxygen consumption (VO2) 
(ml/min/kg), metabolic equivalent of physical effort (METs), estimated energy 
expenditure (kcal/hour), and estimated energy consumed (kcal) on a second by second 
basis [112]. The details regarding this methodology have been described in a previous 
manuscript [113]. As mentioned previously, patients were asked to train within  5 
beats/min of their target heart rate. As such, patient compliance to the prescribed 
intensity was determined by assessing the percent time spent within the target heart rate 
(THR) range (target heart rate  5 beats/min) during the training phase of each cycling 
session. Since patients in the IT group were expected to spend only 50% of their time at 
their THR (during the high interval), the mean compliance to the THR of all patients 
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randomized to that group was obtained for the entire intensity phase and then multiplied 
by two. This was performed due to the inability to precisely identify interval changes on 
the data tracking software. Mean compliance rate was then computed for each subject 
as the average compliance rate maintained throughout the 12-week program. If a 
session was lost due to technical problems, the value from the last available exercise 
session was imputed to replace the lost values (bring the last value forward approach). It 
is important to note that compliance to the prescribed THR was measured only for 
attended sessions.  
Other Measurements 
Self-Efficacy Measures 
As part of the larger RCT, subjects completed a series of psychosocial 
questionnaires, which measured variables associated with quality of life and known to 
change with exercise training [114]. For the present sub-study, baseline exercise self-
efficacy, as measured with the Self-Efficacy Scale (SES) [95, 115]was used to describe 
patients’ confidence in their ability to successfully perform exercise training at entry into 
the program. This questionnaire was self-administered before the start of the 12-week 
pulmonary rehabilitation program. The self-efficacy questionnaire includes the following 
four sections: an exercise compliance sections (8 questions), an exercise endurance 
section (5 questions), an exercise muscle strength section (5 questions), and an 
exercise barriers section (13 questions). The questions in the exercise compliance 
section evaluate how confident patients feel in complying with a pulmonary rehabilitation 
program. For the purpose of the study, questions 5 and 7 of the exercise compliance 
section targeting 6- and 8-week PR programs were removed. Questions regarding 
exercise endurance evaluate the level of confidence that patients have in their capacity 
to endure various exercise durations. Questions in the exercise muscle strength section 
58 
 
aim at evaluating patient’s ability to complete resistance training and questions 
concerning exercise barriers assess patient’s confidence in overcoming obstacles that 
could affect exercising 3 times weekly as part of a PR program. Finally, the scores in the 
self-efficacy questionnaire go from 0 to 100% by increments of 10%, where 0% 
represents not at all confident, 50% represents moderately confident and 100% 
represents highly confident (Appendix D).   
Exercise Measures 
Additional exercise measures, such as heart rate (HR) and exercise workload 
(Watts) achieved during each session attended, were computed for each subject in order 
to have a better idea of the effort accomplished throughout the 12-week program. 
Additional Information gathering 
Information pertaining to subjects’ reasons for absence to the exercise sessions, 
such as respiratory exacerbations, COPD hospitalization, other health reasons and 
personal reasons were recorded throughout the study. 
 
Statistical Analyses 
Mean compliance from week 0 to week 12 was compared between the three 
treatment groups (CTHI, CTV, IT) and was analyzed as mean percent attendance and 
mean percent time patients spent at their target heart rate during the 12-week program. 
Double entry and extraction of the data were performed and only 3 participants out of 36 
had an error and the error was less than 5% in all 3 cases. To evaluate the distribution of 
our results, the skewness (degree to which a variable’s score fall at one, or the other 
ends of the variable’s scale) and Kurtosis (relative frequency of scores in both extremes) 
of variables were evaluated. Levene’s test was conducted to evaluate the homogeneity-
of-variances assumption. If this assumption was met, then one-way repeated-measures 
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analyses of variance (ANOVA), with treatment group as the between-subjects factors 
with three levels (CTHI, CTVT, IT) was executed.  If a significant treatment effect was 
obtained, pairwise comparisons were conducted using Tukey’s honestly significant 
difference (HSD) test to locate between which groups the differences occurred. If on the 
other hand, the Levene’s test rejected the assumption of homogeneity of variances, the 
Welch’s ANOVA was used instead of the usual ANOVA to test between-group 
differences. If a significant treatment effect was obtained, the Games-Howell post-hoc 
test was performed to locate where the difference had occurred.  
To examine the relationship between exercise compliance and each subscale of 
the Self-Efficacy Scale, Pearson’s correlations were conducted. Moreover, interactions 
between the intervention and the SES subscales on compliance rate were analyzed by 
conducting General Linear Model Univariate procedures. All analyses were conducted at 
the 5% level of significance and performed with SPSS version 16.0 (Chicago, IL).   
Power Calculation 
The primary objective of this study was to compare, in individuals with COPD, the 
12-week compliance to three different exercise-training protocols (CTHI, CTVT, IT). The 
sample size for this project was estimated at 36 participants (12 in each group) and the 
primary outcome measure (percent time spent within the target heart rate range) was 
used for the power calculation. Based upon previously reported data [69, 78, 116], the 
total sample of 36 subjects would achieve 80% power to detect differences among the 
means with a 0.05 significance level. The size of the variation in the means is 






Thirty-six subjects (13 males; 23 females) with a mean age of 68 ± 9 years were 
recruited from the outpatient COPD clinic at the Hôpital du Sacré-Coeur de Montréal 
between spring 2009 and fall 2011, and were randomized into the study. The majority of 
our patient sample was Caucasian (97%) and had a mean FEV1 of 1.41 ± 0.42 L with a 
mean percent predicted value of 58.6 ± 17 %, indicating moderate to severe COPD 
(GOLD stage II – III) [6]. At time of study entry, patients had a mean BMI of 27.6 ± 5.1 
Kg.m-2, indicative of an overweight population sample. Subjects randomized to the 
different exercise-training protocols (CTHI, CTVT, and IT) did not differ significantly with 
regards to overall demographic measures, such as age, BMI, FEV1 (in liters and percent 
predicted), and DLCO (Table 4.1). A trend towards a lower FEV1 represented as percent 
predicted was observed in the IT group (Table 4.1). 
 Mean peak work rate and mean peak VO2 on the symptom-limited incremental 
cycling test were 68.2 ± 22.8 Watts and 1.05 ± 0.33 L.min-1 respectively (Table 4.1). 
These measurements did not differ significantly between the three exercise-training 
groups. 
Exercise Attendance and Compliance  
Attendance and compliance rates were both normally distributed, but their 
variance was not homogeneous across the three treatment groups, which led to the use 
of Welch’s ANOVA and Games-Howell post-hoc test.    
The mean attendance rate was 70  33% (range: 2.8 – 100.0%) for CTHI, 82  
17% for CTVT (range: 44.4 – 97.2%), and 63  35% for IT (range: 11.1 -100.0%), with 
no significant difference identified between groups (p= 0.229) (Figure 4.2). As mentioned 
previously, data was not imputed for any missed session. Thus considering the sessions 
that were missed (266 out of 1030 sessions) and by excluding the warm-up and cool-
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down phases (15 min of total exercise-training session), the number of data points 
included in our analysis was approximately 1 545 000. Reasons for lack of attendance to 
training included acute exacerbation of COPD (6.8%), hospitalization due to 
exacerbation (8.6%), other health reasons (doctor appointment, surgery, feeling tired) 
(24.8%) and personal reasons (vacation, work, family problems) (59.8%) (Figure 4.3). 
Eight out of 36 patients (22%) experienced at least 1 exacerbation and the average 
length of symptoms was 5 days. Out of those patients, three were hospitalized for 45, 
10, and 6 days respectively.  
 The mean compliance rate, i.e. the mean percent time spent at the prescribed 
THR, was 85.6 ± 15.0% (range: 44.4 - 96.1%) for CTHI, 84.1 ± 15.1% (range: 40.2 - 
96.4%) for CTVT, and 52.0 ± 41.8% (range: 0.0 -100.0%) for IT (Figure 4.4). The 
difference in compliance rate between exercise-training groups did not reach statistical 
significance (p=0.067), but a trend towards a lower compliance rate in the IT group 
compared to the other two groups was observed. The average heart rate achieved by 
patients throughout the program was 107.9 ± 16.6 bpm, 101.0 ± 11.0 bpm and 112.8 ± 
12.5 bpm for CTHI, CTVT and IT respectively. The watts achieved throughout the 36 
sessions by patients were 37.5 ± 11.9 W (CTHI), 41.6 ± 23.6 W (CTVT) and 46.2 ± 22.4 
(IT). Of note, there were a number of sessions where technical problems caused a loss 
of data. This occurred in 2% of CTHI, 0.9% of CTVT, and 7.5% of IT sessions. This was 
felt to be minor in view of the amount of data collected.  
Exercise Self-Efficacy 
The association between self-efficacy, mean attendance and mean compliance 
scores for CTHI, CTVT, and IT are shown in table 4.2 and partial self-efficacy 
correlations with mean attendance and mean compliance correcting for intervention are 
shown in table 4.3. No significant correlation between self-efficacy subscale scores and 
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compliance (mean attendance and mean time spent at THR) were found. Finally, no 
significant interaction between the intervention and SES subscales on compliance rate 
were found in our study.  
Adverse Events 
No adverse events occurred during the exercise sessions throughout the study.  
 
Discussion 
 The present study compared exercise compliance, using both attendance rate and 
percent time spent at the prescribed training intensity, between three exercise regimens 
in COPD patients: continuous training at high-intensity (CTHI), continuous training at the 
ventilatory threshold (CTVT), and interval training (IT). To our knowledge, this is the 
second study only to use continuous data tracking technology to precisely assess 
exercise compliance in COPD patients and the first original trial to compare compliance 
to these three commonly used exercise-training approaches. Our results did not show 
any significant differences in compliance between the three approaches, but a trend 
towards a lower percent time spent at the target intensity was observed in the group 
undergoing IT.  
  In a previous prospective observational study from Maltais et al. [69], 42 patients 
with moderate to severe COPD completed a 12-week aerobic exercise-training program 
similar to the CTHI approach used in our study. The training program consisted of 3 
weekly sessions of stationary cycling for a target duration of 25-30 minutes and a target 
intensity of 80% of baseline peak work rate (Wpeak). The average attendance rate was 
86 ± 10% and the prescribed training intensity was achieved by 0 (0%), 3 (7%), 5 (12%), 
and 5 (12%) patients at weeks 2, 4, 10, and 12 respectively [69]. In our study, a lower 
attendance rate of 70 ± 33% was observed for the CTHI group but, contrary to Maltais et 
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al’s [69] findings, a majority of patients were able to achieve the target intensity, with a 
mean percent time spent at the THR of 86 ± 15% throughout the 12-week program. 
Patients who underwent CTHI in our trial had less severe airflow obstruction and a better 
exercise tolerance than those who completed Maltais et al’s study, which may explain 
the higher compliance rate in our group. Moreover, although the targeted intensity was 
80% of peak work rate in both studies, the methodology used to ascertain achieved 
intensity was different. In fact, the actual work rate achieved on calibrated ergocycles at 
a fixed pedalling speed was recorded in Maltais et al’s study, while the percent time 
spent at the THR (± 5 beats from the heart rate reached at 80% of peak work rate on the 
incremental cycle test) was extracted in our study. According to the average wattage 
recorded throughout the 12-week program in the CTHI group (37.5 ± 11.9 W) compared 
to their average peak wattage at baseline (65.4 ± 16.2 W), our methodology resulted in 
an intensity closer to 60% of peak work rate. Together with the differences in disease 
severity and exercise tolerance likely explains the much higher compliance rate 
observed in our CTHI patients compared to those who completed Maltais et al’s study.  
In a clinical trial conducted by Puhan and colleagues [78] , patients with severe 
COPD were randomly assigned to either continuous high-intensity or interval training. 
The high-intensity training protocol consisted of pedalling at a target workload of ≥ 70% 
of Wpeak. The interval training protocol involved high-intensity intervals of 20 seconds 
alternated with low-intensity intervals of 40 seconds; the target work rate for the high- 
and low-intensity intervals was, respectively, 50% and 10% of short-term maximum 
exercise capacity, as determined from a previously completed steep ramp test [78]. 
According to the authors, 50% of short-term maximum exercise capacity is equivalent, 
on average, to 90-100% of Wpeak, thus suggesting similar intensities as in our IT 
protocol, but shorter high-intensity intervals (20 seconds versus 30 seconds in our trial), 
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longer low-intensity intervals (40 seconds versus 30 seconds in our trial), and smaller 
work-recovery ratio (1:2 versus 1:1 in our trial). Protocol tolerance was compared by 
looking at the number of unintended breaks of ≥ 1 minute and at the proportion of 
patients achieving the target intensity, as assessed via continuous data tracking 
technology [78]. Interval training was found to be associated with significantly fewer 
unintended breaks and, in contrast to our findings, with better adherence to the planned 
protocol than continuous high-intensity training (48% versus 24%, respectively) [78].In 
our study, a similar compliance rate of 52% was recorded in the IT group, but the 86% 
adherence rate observed in our CTHI group is markedly greater than the 24% reported 
in that study. Although the targeted intensity for continuous high-intensity training was 
theoretically higher in our trial (80% of Wpeak versus 70% of Wpeak in Puhan et al’s 
study), the actual achieved wattage corresponded to approximately 60% of Wpeak in 
both studies. Once again, patients who underwent CTHI in our trial had less severe 
airflow obstruction than those who completed Puhan et al’s study, possibly explaining 
the differences in findings. 
 Lastly, in a randomized controlled trial by Vogiatzis et al. [64], COPD patients were 
either assigned to continuous moderate-intensity or interval training. Patients from both 
groups were asked to perform their exercise sessions on a cycle ergometer, for a period 
of 40 minutes per session and at a frequency of 2 days weekly. The continuous training 
protocol consisted of pedalling at 50% of peak work rate (Wpeak), while the interval 
protocol involved, as in the present study, intervals of 30 seconds at 100% of Wpeak 
alternated with 30 seconds of rest [64]. As in our trial, attendance did not differ between 
both protocols (88 ± 4% in patients undergoing continuous training and 90 ± 4% in 
patients undergoing interval training), but the attendance rates were higher than those 
recorded in our subjects, especially those who underwent IT (63%) in our study. This 
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can likely be explained by the lower training frequency in Vogiatzis et al.’s study, done in 
an attempt to reduce problems with compliance and to ensure greater attendance rates. 
In summary, attendance to CTHI and IT was slightly lower in the present trial than what 
was previously reported [64]. Compliance to IT was similar than what was found in one 
prior randomized study [78]. Lastly, compliance to CTHI was particularly high in the 
present investigation when compared to prior studies [69, 78], possibly because patients 
assigned to CTHI in our trial had less severe disease.  
 An additional aim of the present study was to examine the relationship between 
exercise compliance and baseline self-efficacy scores. No significant correlation was 
found between the four components of self-efficacy (adherence, exercise, strength, and 
obstacle) and mean attendance or mean compliance rates. Contrary to our findings, 
various studies have found a significant relation between self-efficacy and exercise 
behaviour (exercise adoption, adherence and maintenance) [101, 117, 118]. Kaplan and 
Atkins [98] have found that a higher level of self-efficacy was associated with increased 
compliance to exercise prescription. Other studies have found that COPD patients with 
greater self-efficacy feel more confident to perform physical and psychosocial activities 
[54, 101]. However, a study conducted by Vincent et al. [100] found similar results as in 
the present study. Indeed, these investigators used the Pulmonary Rehabilitation 
Adapted Index of Self-efficacy (PRAISE) on 225 patients prior to and on completion of a 
7-week PR program and found no relationship between PRAISE score and completion 
of PR [100]. There could be a few reasons explaining the lack of correlation between 
self-efficacy and attendance and compliance to the THR. Several factors other than self-
efficacy, such as personal factors, can influence attendance and compliance to the PR 
program. These factors could have had a bigger impact on compliance than the baseline 
level of self-efficacy. In addition, a bigger sample size might be needed to reveal a 
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significant correlation between self-efficacy and attendance and compliance to the 
exercise-training programs. 
Limitations and Strengths: 
There were a number of technical challenges in the current study that could have 
affected the reliability of the results. Computer problems occurred causing the loss of 
data during several sessions. To compensate for this technical problem, the last 
exercise session was imputed to replace the lost values. The percentage of lost 
sessions to the overall study was, however, minor in relation to the data accrued and 
likely did not affect the overall results of the study.  Another limitation was that patients 
were required to be cued to change intervals every 30 seconds in the IT group. This 
short interval was difficult from both the patient and health care practitioners supervising 
the exercise sessions. Patients sometimes missed their cue and health care 
practitioners may have missed the exact time to prompt the patient to change their 
intensity. This may have caused an over or under estimation of the compliance rate to 
the prescribed target heart rate in the IT group. This problem may have been overcome 
by identifying the exact moment of interval changes on the CardioMemory tracing.  
However, by not identifying the occurrence of interval change and by expecting patients 
in the IT group to spend only 50% of their time at the prescribed THR for the high 
interval, we were able to account for the delay in the physiologic response that occurs 
during the change between high and low intensities. Lastly, the small number of patients 
per group and the generally low level of disease severity may have affected our findings 
regarding compliance to the different exercise prescriptions and the correlation with 
baseline self-efficacy. 
 The present study also has a number of strengths. It took into consideration both 
attendance rates and compliance to the prescribed training intensity, which permitted a 
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broader and more thorough evaluation of overall exercise compliance. The second-by-
second tracking of each individual exercise session allowed for more specific monitoring 
of patients’ ability to comply with the prescribed exercise intensity. In an attempt to 
determine the optimal prescription in COPD, our study, which was a randomized trial, 
compared compliance to three different-exercise training protocols, contrary to previous 
work which has compared compliance to two different exercise regimens at a time.  
Conclusions: 
 Results from this pilot study showed no significant difference in attendance and 
compliance rates between different exercise-training protocols in patients with moderate 
to severe COPD. However, a trend towards poorer compliance in patients undergoing IT 
compared to those assigned to CTHI and CTVT was observed. Moreover, baseline self-
efficacy scores did not correlate significantly with mean attendance and percent time 
spent at prescribed THR.  Although these findings need to be confirmed in a larger 
sample size, to our knowledge, this study is the first to compare compliance to three 
different exercise-training protocols in COPD. Exercise compliance is essential to the 
effectiveness of PR and without it no therapeutic goal can be achieved [83, 93, 104]. 
This study highlights the benefit of using an innovative and a precise way to track 
adhrence measurements.  
Clinical implications and future directions: 
 This study emphasizes the important role of exercise compliance in order to 
optimize the benefits of PR in COPD. Further studies should focus on factors that 
influence exercise compliance and on interventions that can motivate behavioural 
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Figure 4.1 Overview of study design 
 
Figure 4.2 Mean attendance rate for each exercise-training group 
 
Figure 4.3 Reasons for non attendance 
 























Table 4.1 Characteristics of the study group 
 CTHI CTVT IT p-value 
Male/Female, n 3/9 6/6 4/8  
Age, years 66.3 ± 7.0 69.3 ± 8.8 66.9 ± 10.3 0.670 
BMI, kg.m-2 28.3 ± 5.1 27.1 ± 5.4 27.5 ± 5.3 0.852 
FEV1, L 1.37 ± 0.30 1.60 ± 0.42 1.25 ± 0.48 0.110 
FEV1, % predicted 59.5 ± 15.1 66.2 ± 16.7 50.0 ± 16.6 0.061 
FEV1/FVC, % 51.8 ± 11,5 50.4 ± 9.4 47.4 ± 7.0 0.508 
TLC, % 107.5 ± 22.9 113.0 ± 18.6 112.4 ± 20.9 0.781 
FRC, % 130.7 ± 36.0 136.3 ± 27.5 139.1 ± 26.6 0.792 
RV, % 134.9 ± 44.0 135.8 ± 41.0 146.2 ± 35.6 0.749 
DLCO, ml/CO/mmHg 2.47 ± 0.77 2.12 ± 0.57 2.21 ± 0.80 0.470 
Peak Work Rate, Watts 65.4 ± 16.2 72.1 ± 24.8 67.1 ± 27.4 0.768 
VO2peak, L.min
-1 1.01 ± 0.18 1.07 ± 0.40 1.08 ± 0.38 0.856 
VO2peak, mL.(kg.min)-1 13.54 ± 3.11 14.03 ± 3.75 14.67 ± 3.04 0.618 
Values are presented as Mean ± SD. 
BMI, Body Mass Index; FEV1, Forced Expiratory Volume in 1 second; FVC, Force Vital Capacity; 







*p < 0.05 
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Table 4.3 Partial self-efficacy correlations with mean attendance and mean compliance 
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group and the estimated effect size and 
its precision (e.g., 95% confidence 
interval) 
 60-62 
Ancillary analyses 18 
Address multiplicity by reporting any 
other analyses performed, including 
subgroup analyses and adjusted 
analyses, indicating 
those prespecified and those exploratory 
 61, 62 
Adverse events 19 
All important adverse events or side 





Interpretation of the results, taking into 
account study hypotheses, sources of 
potential bias or imprecision, and the 
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